EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 390 filers reported holding EXELIXIS INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $270,519,256 | +9.8% | 12,380,744 | -4.0% | 0.02% | +15.4% |
| Q2 2023 | $246,352,495 | -2.1% | 12,891,287 | -0.5% | 0.01% | -7.1% |
| Q1 2023 | $251,514,219 | -43.1% | 12,958,195 | -53.0% | 0.01% | +7.7% |
| Q4 2022 | $441,933,054 | +116.5% | 27,551,936 | +111.6% | 0.01% | 0.0% |
| Q3 2022 | $204,152,000 | -22.2% | 13,019,900 | +3.4% | 0.01% | -18.8% |
| Q2 2022 | $262,257,000 | +1.7% | 12,596,380 | +10.7% | 0.02% | +23.1% |
| Q1 2022 | $257,921,000 | +24.9% | 11,377,206 | +0.7% | 0.01% | +30.0% |
| Q4 2021 | $206,548,000 | -7.9% | 11,299,142 | +6.5% | 0.01% | -16.7% |
| Q3 2021 | $224,222,000 | +25.9% | 10,606,520 | +8.5% | 0.01% | +33.3% |
| Q2 2021 | $178,038,000 | -14.7% | 9,771,581 | +5.7% | 0.01% | -25.0% |
| Q1 2021 | $208,742,000 | +1.7% | 9,240,463 | -9.6% | 0.01% | -7.7% |
| Q4 2020 | $205,258,000 | -8.3% | 10,227,119 | +11.7% | 0.01% | -13.3% |
| Q3 2020 | $223,830,000 | -2.5% | 9,154,586 | -5.4% | 0.02% | -11.8% |
| Q2 2020 | $229,617,000 | +17.4% | 9,672,153 | -14.8% | 0.02% | 0.0% |
| Q1 2020 | $195,533,000 | +0.3% | 11,354,975 | +2.6% | 0.02% | +30.8% |
| Q4 2019 | $194,912,000 | +5.5% | 11,061,947 | +5.8% | 0.01% | -7.1% |
| Q3 2019 | $184,822,000 | -14.8% | 10,450,777 | +2.9% | 0.01% | -12.5% |
| Q2 2019 | $216,964,000 | -8.2% | 10,152,741 | +2.3% | 0.02% | -11.1% |
| Q1 2019 | $236,317,000 | +30.0% | 9,929,280 | +7.4% | 0.02% | +5.9% |
| Q4 2018 | $181,777,000 | -9.1% | 9,241,323 | -18.1% | 0.02% | +13.3% |
| Q3 2018 | $199,927,000 | -12.4% | 11,282,667 | +6.4% | 0.02% | -21.1% |
| Q2 2018 | $228,189,000 | +54.5% | 10,603,584 | +59.0% | 0.02% | +46.2% |
| Q1 2018 | $147,728,000 | -18.9% | 6,669,439 | +11.3% | 0.01% | -13.3% |
| Q4 2017 | $182,221,000 | +14.0% | 5,994,182 | -9.1% | 0.02% | +7.1% |
| Q3 2017 | $159,852,000 | -7.6% | 6,597,367 | -6.1% | 0.01% | -6.7% |
| Q2 2017 | $173,035,000 | +3.6% | 7,025,535 | -8.9% | 0.02% | 0.0% |
| Q1 2017 | $167,087,000 | +48.4% | 7,710,338 | +2.1% | 0.02% | +36.4% |
| Q4 2016 | $112,613,000 | +2.9% | 7,553,139 | -11.8% | 0.01% | 0.0% |
| Q3 2016 | $109,483,000 | +120.5% | 8,559,767 | +34.7% | 0.01% | +120.0% |
| Q2 2016 | $49,641,000 | +47.3% | 6,356,435 | -24.6% | 0.01% | +25.0% |
| Q1 2016 | $33,702,000 | -33.1% | 8,425,055 | -5.7% | 0.00% | -33.3% |
| Q4 2015 | $50,372,000 | +15.3% | 8,930,765 | +14.7% | 0.01% | +20.0% |
| Q3 2015 | $43,676,000 | +11.8% | 7,785,299 | -25.1% | 0.01% | +25.0% |
| Q2 2015 | $39,061,000 | +32.4% | 10,388,996 | -9.5% | 0.00% | +33.3% |
| Q1 2015 | $29,513,000 | +34.4% | 11,482,521 | -24.7% | 0.00% | +50.0% |
| Q4 2014 | $21,952,000 | +24.9% | 15,244,566 | +32.6% | 0.00% | 0.0% |
| Q3 2014 | $17,582,000 | -28.1% | 11,494,043 | +59.3% | 0.00% | -33.3% |
| Q2 2014 | $24,468,000 | +13.8% | 7,217,244 | +18.9% | 0.00% | +50.0% |
| Q1 2014 | $21,492,000 | -66.8% | 6,071,249 | -50.4% | 0.00% | -50.0% |
| Q4 2013 | $64,772,000 | +73.4% | 12,241,918 | +90.7% | 0.00% | -20.0% |
| Q3 2013 | $37,352,000 | +51.0% | 6,418,151 | +17.8% | 0.01% | +66.7% |
| Q2 2013 | $24,736,000 | – | 5,447,925 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
| Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
| Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
| Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
| TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
| CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
| Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
| Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
| Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |